Study Summary
This trial employs a single-arm, open-label seamless Phase I/II design, consisting of two stages: Phase I dose exploration and Phase II dose expansion.The primary objective of this trial is to evaluate the safety, tolerability, and efficacy of subretinal injection of ZVS203e solution.
Want to learn more about this trial?
Request More InfoInterventions
ZVS203eDRUG
ZVS203e injection is a clear, transparent liquid containing a recombinant adeno-associated virus serotype 8 (rAAV8) vector that expresses humanized SauriCas9 protein and single guide RNA (sgRNA) targeting specific mutations in the RHO gene.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Peking University Third Hospital | Beijing | Beijing Municipality | China |